These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452 [TBL] [Abstract][Full Text] [Related]
47. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339 [TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant therapy vs. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis. Xu Y; Chen Y; Han F; Wu J; Zhang Y Biosci Trends; 2022 Jan; 15(6):365-373. PubMed ID: 34759120 [TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Lee YS; Lee JC; Yang SY; Kim J; Hwang JH Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626 [TBL] [Abstract][Full Text] [Related]
50. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490 [TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297 [TBL] [Abstract][Full Text] [Related]
52. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811 [TBL] [Abstract][Full Text] [Related]
53. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840 [TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547 [TBL] [Abstract][Full Text] [Related]
55. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M; BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786 [TBL] [Abstract][Full Text] [Related]
56. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444 [TBL] [Abstract][Full Text] [Related]
57. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767 [TBL] [Abstract][Full Text] [Related]
58. Impact of preoperative staging and chemoradiation versus postoperative chemoradiation on outcome in patients with rectal cancer: a decision analysis. Telford JJ; Saltzman JR; Kuntz KM; Syngal S J Natl Cancer Inst; 2004 Feb; 96(3):191-201. PubMed ID: 14759986 [TBL] [Abstract][Full Text] [Related]
59. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. He J; Schulick RD; Del Chiaro M Ann Surg Oncol; 2021 Mar; 28(3):1514-1520. PubMed ID: 33415556 [TBL] [Abstract][Full Text] [Related]
60. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]